Literature DB >> 24909697

Congenital aural atresia and stenosis: surgery strategies and long-term results.

Chenlong Li1, Tianyu Zhang, Yaoyao Fu, Fenghua Qing, Fanglu Chi.   

Abstract

OBJECTIVE: To compare the patients who underwent surgery for congenital aural atresia (CAA) with congenital aural stenosis (CAS) for the stability of hearing results and complications during long-term follow-up.
DESIGN: Retrospective review. STUDY SAMPLE: Seventy-five CAA patients and fifty CAS patients who underwent congenital meatoplasty with canalplasty and tympanoplasty between 2007 and 2012.
RESULTS: Paired comparison analyses detected no significant difference in preoperative ABG but significant changes in postoperative ABG, ΔABG, the number of ABG < 30 dB and ABG < 10 dB between CAA and CAS. Complications such as postoperative stenosis, bony regrowth, external aural canal (EAC) infection, EAC eczema, total deaf, and lateralization of the tympanic membrane (TM) were observed in 61.3% of patients with CAA and 20% of patients with CAS. Chi square test detected significant differences in complications between patients with CAA and CAS (χ(2) = 20.73, p < 0.01).
CONCLUSION: Meatoplasty with canalplasty and tympanoplasty in individuals with CAS can yield reliable and lasting positive hearing results with a low incidence of severe complications. The existence and preoperative condition of patients' TM and EAC skin helped improve hearing results and decrease the incidence of complications. However, the final hearing results and complications required stricter indications for CAA patients.

Entities:  

Keywords:  Pediatric; hearing conservation; medical audiology; middle ear

Mesh:

Year:  2014        PMID: 24909697     DOI: 10.3109/14992027.2014.890295

Source DB:  PubMed          Journal:  Int J Audiol        ISSN: 1499-2027            Impact factor:   2.117


  1 in total

1.  Congenital Aural Stenosis: Clinical Features and Long-term Outcomes.

Authors:  Chen-Long Li; Ying Chen; Yong-Zheng Chen; Yao-Yao Fu; Tian-Yu Zhang
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.